DailyIQ
|
Sector:HealthcareAll sectors
Last updated 23 minutes ago

MDLN·MDLN

$.
+. (+.%)
High
$45.43
Open
$44.61
Market Cap
58.53B
52W High
$47.99
Low
$44.03
P. Close
$36.06
P/E
48.77
52W Low
$34.89
Fwd P/E
-
Mean Target
-
Technical Score (1D)
0
SELL
News Sentiment
54
MIXED
Medline (MDLN) is an ETF that provides exposure to the healthcare sector, and recent developments suggest a positive outlook for the underlying holdings. Carlyle's Q4 earnings call highlighted the successful IPO of MDLN, which contributed to the company's strong performance. This positive market reception, with revenue exceeding expectations, may indicate favorable conditions for other healthcare companies considering IPOs. Carlyle's report also emphasized robust global fundraising, private equity exits, and record inflows, which could signal increased investment activity in the healthcare sector. The strong performance of Carlyle's buyout funds, driven in part by portfolio IPOs, further supports the positive sentiment. This suggests potential for growth in the healthcare sector, as companies may seek to capitalize on favorable market conditions. The focus on MDLN's IPO during the earnings call also suggests positive implications for Carlyle's portfolio, potentially boosting investor confidence in healthcare-related investments. However, it's important to note that the valuation of MDLN is being assessed, with a recent share price rally examined. The article notes a valuation score of 2 out of 6, which may indicate potential undervaluation. Investors should watch for further developments in the healthcare sector, including IPO activity and fundraising trends, to gauge the overall market sentiment.
Earnings Summary
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally, operating through two segments: Medline Brand and Supply Chain Solutions, placing it within the Healthcare sector and Medical Instruments & Supplies industry. Not enough information is available to compare recent quarterly performance. Not enough information is available to analyze historical streak. Today, two financial firms initiated coverage of Medline with Buy ratings, which could signal increased confidence in Medline's future performance. Investors should watch for the actual Q4 2025 earnings results to assess the company's financial performance and the impact of recent analyst ratings.

EPS

EstBeatMiss
$-0.05$0.04$0.12$0.21$0.29Q4'25
QtrEstActual+/−
Q4'25$0.25$-0.01-103.9%

Revenue

EstBeatMiss
$7.7B$7.7B$7.7B$7.8B$7.8BQ4'25
QtrEstActual+/−
Q4'25$7.7B$7.8B+1.2%
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

MDLN Stock Snapshot

MDLN is currently trading at $36.54, giving MDLN a market cap of 58.53B and a P/E ratio of 48.8. Today's range spans $44.03–$45.43, with shares opening at $44.61 and moving up $0.48 (1.3%) from the prior close. DailyIQ's technical score sits at 0/100 (SELL) with a news sentiment reading of 54/100.

Over the past year MDLN has traded between $34.89 and $47.99 - the current price is +4.7% off the 52-week low and -23.9% from the high.

Risk is elevated for MDLN (MDLN) right now - bearish technical setup (0/100, SELL), neutral sentiment (54/100), price $36.54 (near 52-week lows). The current P/E ratio stands at 48.8. At 58.53B in Healthcare market cap, the 52-week range of $34.89–$47.99 defines where structural demand might resurface - because at this capitalization tier, buyers don't disappear, they just move their bids to different price levels.

When a large-cap Healthcare name with 58.53B in capitalization prints a SELL signal (0/100) alongside neutral news sentiment (54/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $36.54 (near 52-week lows in the $34.89–$47.99 range), the structural support levels are where that sponsorship question gets answered.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…